Teva Pharmaceutical Industries (TEVJF) Operating Expenses (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Operating Expenses across 10 years of filings, most recently posting $526.0 million for Q1 2026.

• Quarterly Operating Expenses fell 3.31% year-over-year to $526.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 4.54% YoY) and the FY2025 annual result came in at $2.3 billion, up 6.53% from the prior year.
• Operating Expenses eased to $526.0 million in Q1 2026, from $634.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $634.0 million in Q4 2025 and troughed at $458.0 million in Q3 2022.
• A 5-year average of $536.5 million and a median of $538.0 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses declined 10.72% — and 2025, when it increased 15.48%.
• Tracing TEVJF's Operating Expenses over 5 years: stood at $498.0 million in 2022, then gained by 4.22% to $519.0 million in 2023, then increased by 5.78% to $549.0 million in 2024, then advanced by 15.48% to $634.0 million in 2025, then fell by 17.03% to $526.0 million in 2026.
• Business Quant data shows TEVJF's Operating Expenses at $526.0 million in Q1 2026, $634.0 million in Q4 2025, and $573.0 million in Q3 2025.